Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

138 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Oxidative stress mediates an increased formation of vascular endothelial growth factor in human hepatocarcinoma cells exposed to erlotinib.
Rohr-Udilova N, Klinglmüller F, Seif M, Hayden H, Bilban M, Pinter M, Stolze K, Sieghart W, Peck-Radosavljevic M, Trauner M. Rohr-Udilova N, et al. Among authors: hayden h. Oncotarget. 2017 Jul 6;8(34):57109-57120. doi: 10.18632/oncotarget.19055. eCollection 2017 Aug 22. Oncotarget. 2017. PMID: 28915658 Free PMC article.
Impact of glutathione peroxidase 4 on cell proliferation, angiogenesis and cytokine production in hepatocellular carcinoma.
Rohr-Udilova N, Bauer E, Timelthaler G, Eferl R, Stolze K, Pinter M, Seif M, Hayden H, Reiberger T, Schulte-Hermann R, Peck-Radosavljevic M, Stoiber D, Trauner M. Rohr-Udilova N, et al. Among authors: hayden h. Oncotarget. 2018 Jan 22;9(11):10054-10068. doi: 10.18632/oncotarget.24300. eCollection 2018 Feb 9. Oncotarget. 2018. PMID: 29515790 Free PMC article.
Erlotinib and sorafenib in an orthotopic rat model of hepatocellular carcinoma.
Sieghart W, Pinter M, Dauser B, Rohr-Udilova N, Piguet AC, Prager G, Hayden H, Dienes HP, Dufour JF, Peck-Radosavljevic M. Sieghart W, et al. Among authors: hayden h. J Hepatol. 2012 Sep;57(3):592-9. doi: 10.1016/j.jhep.2012.04.034. Epub 2012 May 24. J Hepatol. 2012. PMID: 22634341
Nebivolol treatment increases splanchnic blood flow and portal pressure in cirrhotic rats via modulation of nitric oxide signalling.
Reiberger T, Payer BA, Schwabl P, Hayden H, Horvatits T, Jäger B, Hummel T, Mitterhauser M, Trauner M, Fuhrmann V, Angermayr B, Peck-Radosavljevic M; Vienna Hepatic Hemodynamic Lab. Reiberger T, et al. Among authors: hayden h. Liver Int. 2013 Apr;33(4):561-8. doi: 10.1111/liv.12101. Epub 2013 Jan 20. Liver Int. 2013. PMID: 23331709
The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction.
Schwabl P, Hambruch E, Seeland BA, Hayden H, Wagner M, Garnys L, Strobel B, Schubert TL, Riedl F, Mitteregger D, Burnet M, Starlinger P, Oberhuber G, Deuschle U, Rohr-Udilova N, Podesser BK, Peck-Radosavljevic M, Reiberger T, Kremoser C, Trauner M. Schwabl P, et al. Among authors: hayden h. J Hepatol. 2017 Apr;66(4):724-733. doi: 10.1016/j.jhep.2016.12.005. Epub 2016 Dec 18. J Hepatol. 2017. PMID: 27993716 Free article.
Synergistic effects of erlotinib and everolimus on bronchial carcinoids and large-cell neuroendocrine carcinomas with activated EGFR/AKT/mTOR pathway.
Bago-Horvath Z, Sieghart W, Grusch M, Lackner A, Hayden H, Pirker C, Komina O, Węsierska-Gądek J, Haitel A, Filipits M, Berger W, Schmid K. Bago-Horvath Z, et al. Among authors: hayden h. Neuroendocrinology. 2012;96(3):228-37. doi: 10.1159/000337257. Epub 2012 Apr 27. Neuroendocrinology. 2012. PMID: 22378048
The soluble guanylate cyclase stimulator riociguat reduces fibrogenesis and portal pressure in cirrhotic rats.
Schwabl P, Brusilovskaya K, Supper P, Bauer D, Königshofer P, Riedl F, Hayden H, Fuchs CD, Stift J, Oberhuber G, Aschauer S, Bonderman D, Gnad T, Pfeifer A, Uschner FE, Trebicka J, Rohr-Udilova N, Podesser BK, Peck-Radosavljevic M, Trauner M, Reiberger T. Schwabl P, et al. Among authors: hayden h. Sci Rep. 2018 Jun 19;8(1):9372. doi: 10.1038/s41598-018-27656-y. Sci Rep. 2018. PMID: 29921982 Free PMC article.
Dual inhibition of EGFR and mTOR pathways in small cell lung cancer.
Schmid K, Bago-Horvath Z, Berger W, Haitel A, Cejka D, Werzowa J, Filipits M, Herberger B, Hayden H, Sieghart W. Schmid K, et al. Among authors: hayden h. Br J Cancer. 2010 Aug 24;103(5):622-8. doi: 10.1038/sj.bjc.6605761. Epub 2010 Aug 3. Br J Cancer. 2010. PMID: 20683448 Free PMC article.
138 results